Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma

@article{Aita1999PharmacokineticsOO,
  title={Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma},
  author={Paola Aita and Isabelle Robieux and Roberto Sorio and Salvatore Tumolo and Giuseppe Corona and Renato Cannizzaro and Anna Maria Colussi and Mauro Boiocchi and G Toffoli},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1999},
  volume={43},
  pages={287-294}
}
Etoposide dosage in patients with liver dysfunction remains controversial. Since etoposide has a hepatic component to its clearance (CL) and shows a high degree of protein binding, hepatic impairment could affect etoposide disposition. However, the empiric recommendation that the dose of etoposide be decreased in such patients may reduce systemic exposure and be detrimental to its antitumor activity. To address these issues we studied the pharmacokinetics (PK) of etoposide in patients with… CONTINUE READING